drugset / Trial / NCT00214578

Seroquel on Glucose Metabolism

NCT00214578 ↗

Phase 4 Completed 572 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether six months treatment with the antipsychotic medicine Seroquel (quetiapine) may affect the schizophrenic patient's glucose metabolism

Timeline

Start
2004-04
Primary completion
—
Completion
2005-10

Outcome

Met primary endpoint

paper was significantly lower for quetiapine versus olanzapine (t = 1.98, df = 377, p = .048). PMID 19358783 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule — —

Indications